Invitrogen Gains FDA Premarket Approval for HER2 Test | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen said today that it has received US Food and Drug Administration premarket approval for its SPOT-Light HER2 CISH kit, which can be used to assess whether breast cancer patients should be treated with Genentech’s Herceptin (trastuzumab).
Invitrogen said that this is the first premarket approval that it has received from the FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.